Literature DB >> 23760942

High serum CA19-9 levels are associated with an increased risk of cholangiocarcinoma in patients with intrahepatic duct stones: a case-control study.

Jung Hyun Jo1, Moon Jae Chung, Jeong Youp Park, Seungmin Bang, Seung Woo Park, Kyung Sik Kim, Woo Jung Lee, Si Young Song, Jae Bock Chung.   

Abstract

BACKGROUND: Hepatolithiasis is a known risk factor for cholangiocarcinoma (CC). Due to the high risk of complications that accompany endoscopic and surgical stone removal, it is often difficult to decide whether it is beneficial to remove intrahepatic ductal stones. We conducted a case-control study to determine the risk of developing CC and the benefit of stone removal in patients with hepatolithiasis.
METHODS: Twenty-three patients with CC group between 2002 and 2012 were included in this study. For each patient with CC, four control patients with hepatolithiasis were enrolled based on age and sex matching. Finally, 115 patients with hepatolithiasis were enrolled.
RESULTS: The mean length of time that intrahepatic stones were present was 116.57 (± 98.77) months in the CC group and 80.56 (± 101.10) months in the control group. History of gastrectomy [OR 5.756 (1.329-24.930), p = 0.019], history of choledochoenterostomy (OR 4.938 [1.129-21.595], p = 0.034), serum CA19-9 level [OR 1.001 (1.000-1.001), p = 0.022], and complete removal of stones [OR 0.167 (0.052-0.539), p = 0.003] were independent predictive factors of CC. In patients who had undergone incomplete removal of stones, the occurrence of CC was significantly reduced overall as well as in a subgroup of patients with elevated CA19-9 (p = 0.015 and p = 0.006, respectively) compared to patients with a CA19-9 of <22 U/mL (p = 0.477).
CONCLUSIONS: History of gastrectomy or choledochoenterostomy, high levels of serum CA19-9, and incomplete removal of stones were potential predictive factors of CC in patients with hepatolithiasis. Additionally, complete removal of stones may reduce the risk of CC in patients with high serum CA19-9 levels (>22 U/mL).

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23760942     DOI: 10.1007/s00464-013-3025-1

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   4.584


  14 in total

1.  Risk factors of intrahepatic cholangiocarcinoma in patients with hepatolithiasis: a case-control study.

Authors:  Zhen-Yu Liu; Yan-Ming Zhou; Le-Hua Shi; Zheng-Feng Yin
Journal:  Hepatobiliary Pancreat Dis Int       Date:  2011-12

2.  Management of common bile duct injury during partial gastrectomy.

Authors:  Jennifer A Dixon; Katherine A Morgan; David B Adams
Journal:  Am Surg       Date:  2009-08       Impact factor: 0.688

Review 3.  Pathogenesis of cholesterol and pigment gallstones: an update.

Authors:  Karel Johannes Van Erpecum
Journal:  Clin Res Hepatol Gastroenterol       Date:  2011-02-25       Impact factor: 2.947

Review 4.  Risk factors for cholangiocarcinoma.

Authors:  Gia L Tyson; Hashem B El-Serag
Journal:  Hepatology       Date:  2011-07       Impact factor: 17.425

5.  Factors predicting concurrent cholangiocarcinomas associated with hepatolithiasis.

Authors:  Y-T Kim; J S Byun; J Kim; Y H Jang; W J Lee; J K Ryu; S W Kim; Y B Yoon; C Y Kim
Journal:  Hepatogastroenterology       Date:  2003 Jan-Feb

6.  Hepaticojejunostomy for hepatolithiasis: a critical appraisal.

Authors:  Shao-Qiang Li; Li-Jian Liang; Bao-Gang Peng; Jia-Ming Lai; Ming-De Lu; Dong-Ming Li
Journal:  World J Gastroenterol       Date:  2006-07-14       Impact factor: 5.742

Review 7.  Gallstone disease: Management of intrahepatic stones.

Authors:  Toshiyuki Mori; Masanori Sugiyama; Yutaka Atomi
Journal:  Best Pract Res Clin Gastroenterol       Date:  2006       Impact factor: 3.043

8.  Mucosal dysplasia of the liver and the intraductal variant of peripheral cholangiocarcinoma in hepatolithiasis.

Authors:  T Ohta; T Nagakawa; N Ueda; T Nakamura; T Akiyama; K Ueno; I Miyazaki
Journal:  Cancer       Date:  1991-11-15       Impact factor: 6.860

9.  Changing patterns of gallstone disease in Korea.

Authors:  Yong-Hyun Park; Sang-Jae Park; Jin-Young Jang; Young Joon Ahn; Youn-Chan Park; Yong Bum Yoon; Sun-Whe Kim
Journal:  World J Surg       Date:  2004-01-08       Impact factor: 3.352

10.  Hepatitis B virus infection and intrahepatic cholangiocarcinoma in Korea: a case-control study.

Authors:  Tae Y Lee; Sang S Lee; Seok W Jung; Seong H Jeon; Sung-Cheol Yun; Hyoung-Chul Oh; Seunghyun Kwon; Sung K Lee; Dong W Seo; Myung-Hwan Kim; Dong J Suh
Journal:  Am J Gastroenterol       Date:  2008-06-28       Impact factor: 10.864

View more
  4 in total

1.  Risk Factors for Cholangiocarcinoma After Initial Hepatectomy for Intrahepatic Stones.

Authors:  Ze-Wu Meng; Sheng-Hua Han; Jin-Hai Zhu; Liang-Yi Zhou; Yan-Ling Chen
Journal:  World J Surg       Date:  2017-03       Impact factor: 3.352

Review 2.  Hepatolithiasis and intrahepatic cholangiocarcinoma: A review.

Authors:  Hyo Jung Kim; Jae Seon Kim; Moon Kyung Joo; Beom Jae Lee; Ji Hoon Kim; Jong Eun Yeon; Jong-Jae Park; Kwan Soo Byun; Young-Tae Bak
Journal:  World J Gastroenterol       Date:  2015-12-28       Impact factor: 5.742

3.  Diagnostic and prognostic serum marker of cholangiocarcinoma (Review).

Authors:  Xiaojun Zeng; Hualin Tao
Journal:  Oncol Lett       Date:  2014-11-10       Impact factor: 2.967

4.  Significant increased CA199 levels in acute pancreatitis patients predicts the presence of pancreatic cancer.

Authors:  Dongling Teng; Keyan Wu; Yunyun Sun; Min Zhang; Dan Wang; Jian Wu; Tao Yin; Weijuan Gong; Yanbing Ding; Weiming Xiao; Guotao Lu; Weiqin Li
Journal:  Oncotarget       Date:  2018-01-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.